Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study

Categoría Estudio primario
RevistaThe Journal of rheumatology
Año 2025

Este artículo no está incluido en ninguna revisión sistemática

Este artículo es parte de los siguientes hilos de publicación
Cargando información sobre las referencias
Objective. This study examined the effect of dose step-down in patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib 4 mg once daily for up to 96 weeks. Methods. Patients who completed a baricitinib phase III study could enter a long-term extension (LTE). In the LTE, patients who received baricitinib 4 mg for ≥ 15 months and maintained Clinical Disease Activity Index (CDAI) low disease activity (LDA) or remission (REM) were blindly randomized to continue with 4 mg or taper to 2 mg. If needed, 2-mg–treated patients could be rescued to 4 mg, and 4-mg–treated patients could be rescued by adding or increasing conventional synthetic disease-modifying antirheumatic drugs. Efficacy and safety were assessed through 96 weeks. Nonresponder imputation (NRI), considering rescued or discontinued patients as nonresponders, was used for CDAI response analyses. Results. At 96 weeks, most patients maintained LDA in both 2-mg and 4-mg arms, with a lower maintenance rate in the 2-mg than the 4-mg group (NRI 59.9% and 70.2%, respectively). Patients maintained REM in the 2-mg and 4-mg arms at 30.8% and 36.6%, respectively. Rescue rates were 14.7% for baricitinib 4 mg and 22.5% for 2 mg. Of 112 patients who lost LDA in the 2-mg arm and were rescued to 4 mg, 76.2% and 75.6% achieved LDA again at 12 and 24 weeks postrescue, respectively. Conclusion. In a randomized, blinded, phase III LTE study, maintenance of disease control following induction of sustained LDA/REM with baricitinib 4 mg was greater with continued 4 mg than after tapering to 2 mg. Nonetheless, 76% of patients tapered to 2 mg could maintain LDA/REM or recapture with return to 4 mg, if needed. © 2025 The Journal of Rheumatology.
Epistemonikos ID: 2bb3791498a4d0307e4a873b71fbc508ceb4f291
First added on: Jan 16, 2025